Atara Biotherapeutics | 8-K: Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Atara Biotherapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations
Atara Biotherapeutics | 8-K: Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
Atara Biotherapeutics | DEFA14A: Others
Atara Biotherapeutics | DEF 14A: Definitive information statements
Atara Biotherapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | 8-K: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Atara Biotherapeutics | 8-K: Current report
Atara Biotherapeutics | 8-K: Current report
No Data